Pharmaceutical industry executive with experience in developing products in ophthalmic, neurological, dermatological, and infectious disease areas. Key accomplishments and contributions to the life sciences community,• Built and led high-performing global organizations that contributed to development of a wide variety of patient-centric pharmaceutical and drug-device combination products. Commercial products include, Ozurdex®, Durysta™, Latisse®, Qulipta™, Ubrelvy™, Tripligan®, Omnicef® 250mg/5mL, Aczone® Gel 7.5%, Rhofade®, SeysaraTM, Noctiva™, Restasis MultiDose™, Ganfort® PF (EU), Vuity®, Refresh Optive Mega-3®, Optive Fusion® • Inventor on US & WIPO patents in drug delivery, formulations, and product design• Global CMC regulatory filings experience and represented company at Agency meetings in US, EU, Asia & South America• Led CMC due diligence for partnerships/acquisitions and represented company on Joint Development Committees• United States Pharmacopeia (USP) Dosage Forms Expert Committee member (2015 – 2020) & USP <771> Ophthalmic Preparation Expert Panel (2015 – Present)• Board of Directors, International Consortium for Innovation & Quality in Pharmaceutical Development (2019 - 2023)• Chairman, Industrial Advisory Board, National Science Foundation’s Center for Pharmaceutical Processing Research (2007-2008). Board member (2002 - 2020)• Faculty Member for training sessions on Pharmaceutical Unit Operations intended for FDA members in OPS/ONDQA (2007 and 2009)• Product Quality Research Institute (PQRI), Drug Substance Technical Committee, Physical Properties Working Group (Section Leader, 2002-2007)• Adjunct Professor, IMPH Dept, Purdue University, West Lafayette, IN (2002 - 2019)